Abstract
Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent
episodes of angioedema, and caused by a deficiency of the plasma protein C1 inhibitor.
HAE attacks carry a substantial risk of morbidity or even mortality, making it imperative
that the correct diagnosis be established and an appropriate management plan be in
place. This report reviews the current diagnostic and therapeutic approaches available
in the United States. Areas in which the diagnostic or therapeutic tools are deficient
are discussed, and the prospects for improved therapeutic modalities highlighted.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′1-esterase.Am. J. Med. 1963; 35: 37-44
- C1 inhibitor and hereditary angioneurotic edema.Annu. Rev. Immunol. 1988; 6: 595-628
- C1 inhibitors and their genes: an update.J. Lab. Clin. Med. 1992; 119: 330-333
- Molecular defects in hereditary angioneurotic edema.Proc. Assoc. Am. Physicians. 1997; 109: 164-173
- Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype–phenotype correlations in angiodema [see comments].Am. J. Hum. Genet. 1996; 59: 308-319
- Detection of C1 inhibitor mutations in patients with hereditary angioedema.J. Allergy Clin. Immunol. 2000; 105: 541-546
- Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.J. Allergy. 1962; 33: 330-341
- Detection of active kallikrein in induced blister fluids of hereditary angioedema patients.J. Exp. Med. 1980; 152: 742-747
- Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin.J. Allergy Clin. Immunol. 1983; 72: 54-60
- Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.N. Engl. J. Med. 1983; 308: 1050-1054
- Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.J. Clin. Invest. 1986; 78: 567-575
- Plasma bradykinin in angio-oedema.Lancet. 1998; 351: 1693-1697
- Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.J. Clin. Invest. 2002; 109: 1057-1063
- Hereditary angioedema: the clinical syndrome and its management.Ann. Int. Med. 1976; 84: 586-593
- Hereditary angioedema: a broad review for clinicians.Arch. Int. Med. 2001; 161: 2417-2429
- Hereditary angioneurotic edema: two genetic variants.Science. 1965; 148: 957-958
- Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema.J. Allergy Clin. Immunol. 2000; 106: 546-550
- Hereditary angioedema with normal C1-inhibitor activity in women.Lancet. 2000; 356: 213-217
- Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema.J. Allergy Clin. Immunol. 2000; 106: 1147-1154
- The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency.J. Allergy Clin. Immunol. 1986; 78: 1115-1120
- Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema).Ann. Int. Med. 1960; 53: 739-745
- Successful use of oxandrolone in the prophylaxis of hereditary angioedema: a case report.Pediatr. Asthma, Allergy Immunol. 1999; 13: 189-193
- Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients.J. Allergy Clin. Immunol. 1997; 99: 194-196
- Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema.Lancet. 1999; 353: 1066-1067
- Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. a double-blind study.N. Engl. J. Med. 1972; 286: 808-812
- Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.N. Engl. J. Med. 1996; 334: 1630-1634
- Use of purified C1 esterase inhibitor in patients with hereditary angioedema. Reply.Anesthesiology. 1990; 72: 957
- Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.N. Engl. J. Med. 1980; 302: 542-546
- Hereditary angio-oedema: treatment with C1 esterase inhibitor concentrate.J. R. Soc. Med. 1984; 77: 1046-1048
- Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate.Ann. Allergy. 1980; 44: 299-301
- C1 INH concentrate in the therapy of hereditary angioedema.Allergy. 1983; 38: 81-84
- Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.Arch. Int. Med. 2001; 161: 714-718
- C1-inhibitor: an anti-inflammatory reagent with therapeutic potential.Expert Opin. Pharmacother. 2001; 2: 1073-1083
- Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy.Am. J. Med. 2003; 114: 294-298
Article info
Identification
Copyright
© 2003 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
